Caseware UK (AP4) 2024.0.164 2024.0.164 2024-03-312024-03-31true2023-04-01falseNo description of principal activity11falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 11508236 2023-04-01 2024-03-31 11508236 2022-04-01 2023-03-31 11508236 2024-03-31 11508236 2023-03-31 11508236 c:Director1 2023-04-01 2024-03-31 11508236 d:MotorVehicles 2023-04-01 2024-03-31 11508236 d:MotorVehicles 2024-03-31 11508236 d:MotorVehicles 2023-03-31 11508236 d:MotorVehicles d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 11508236 d:OfficeEquipment 2023-04-01 2024-03-31 11508236 d:OfficeEquipment 2024-03-31 11508236 d:OfficeEquipment 2023-03-31 11508236 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 11508236 d:ComputerEquipment 2023-04-01 2024-03-31 11508236 d:ComputerEquipment 2024-03-31 11508236 d:ComputerEquipment 2023-03-31 11508236 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 11508236 d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 11508236 d:CurrentFinancialInstruments 2024-03-31 11508236 d:CurrentFinancialInstruments 2023-03-31 11508236 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 11508236 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 11508236 d:ShareCapital 2024-03-31 11508236 d:ShareCapital 2023-03-31 11508236 d:RetainedEarningsAccumulatedLosses 2024-03-31 11508236 d:RetainedEarningsAccumulatedLosses 2023-03-31 11508236 c:FRS102 2023-04-01 2024-03-31 11508236 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 11508236 c:FullAccounts 2023-04-01 2024-03-31 11508236 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 11508236 2 2023-04-01 2024-03-31 11508236 6 2023-04-01 2024-03-31 11508236 e:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure

Registered number: 11508236










KREIS MEDICAL LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2024

 
KREIS MEDICAL LIMITED
REGISTERED NUMBER: 11508236

STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 3 
39,178
57,708

Investments
 4 
31
31

  
39,209
57,739

Current assets
  

Debtors: amounts falling due within one year
 5 
287,563
311,622

Cash at bank and in hand
  
140,719
11,982

  
428,282
323,604

Creditors: amounts falling due within one year
 6 
(42,123)
(37,320)

Net current assets
  
 
 
386,159
 
 
286,284

Total assets less current liabilities
  
425,368
344,023

  

Net assets
  
425,368
344,023


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
425,268
343,923

  
425,368
344,023


Page 1

 
KREIS MEDICAL LIMITED
REGISTERED NUMBER: 11508236
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2024

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Daniela Kreis-Alsayed
Director

Date: 23 April 2025

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
KREIS MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Kreis Medical Limited is a private company limited by shares and incorporated in England and Wales, registration number 11508236. The registered office is Elizabeth Courtauld Partnership, Factory Lane West, Halstead, Essex, United Kingdom, CO9 1EX.
The financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest £. 
The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of turnover can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 3

 
KREIS MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using either the straight-line or reducing balance method.

Depreciation is provided on the following basis:

Motor vehicles
-
33%
Reducing balance
Office equipment
-
25%
Straight line
Computer equipment
-
33%
Straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Income statement for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in profit or loss for the period.

Page 4

 
KREIS MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.11

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

 
2.12

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 5

 
KREIS MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

3.


Tangible fixed assets





Motor vehicles
Office equipment
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 April 2023
55,665
2,957
2,975
61,597


Additions
-
-
1,199
1,199



At 31 March 2024

55,665
2,957
4,174
62,796



Depreciation


At 1 April 2023
792
1,395
1,702
3,889


Charge for the year on owned assets
18,108
710
911
19,729



At 31 March 2024

18,900
2,105
2,613
23,618



Net book value



At 31 March 2024
36,765
852
1,561
39,178



At 31 March 2023
54,873
1,562
1,273
57,708


4.


Fixed asset investments





Fixed asset investments

£



Cost or valuation


At 1 April 2023
31



At 31 March 2024
31




Page 6

 
KREIS MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

5.


Debtors

2024
2023
£
£


Trade debtors
96,288
82,759

Other debtors
188,751
227,407

Prepayments and accrued income
2,524
1,456

287,563
311,622



6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Corporation tax
38,207
19,936

Other creditors
-
14,175

Accruals and deferred income
3,916
3,209

42,123
37,320



7.


Related party transactions

At the year end date, the director owed the company £128,127 (2023: £171,231).

 
Page 7